Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912331585> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2912331585 abstract "Commercialized intravenous immunoglobulin (IVIG) products have been used since the early 1980s for various patient treatment options, specifically to induce an immunomodulatory and therapeutic effect. IVIG, a pooled immunoglobulin G (IgG) preparation, is used for patients with immune deficiencies, inflammatory conditions, and autoimmune disorders such as primary immune thrombocytopenia (ITP). Front-line therapies for ITP include corticosteroids, IVIG, or anti-RhD immune globulin (RhIG). WinRho SDF (Cangene Corporation, Winnipeg, Manitoba, Canada), a RhIG preparation, was FDA-approved for use in 2005 and is used for treatment of patients with ITP through what is called a Fc blockade mechanism. After intravenous WinRho administration, patient platelets are spared from clearance by the spleen and with a good response to treatment, the patient9s platelet count increases. WinRho is not without potential side effects and also impacts the transfusion service pre-transfusion testing in the event that the patient undergoing treatment requires red cell transfusion. In 2010, a work group of experts reviewed the warnings associated with RhIG and concluded that assuming that patients are appropriate candidates for RhIG, monitored in a clinical setting for 8 hours after administration, RhIG products such as WinRho are considered a very effective front-line therapy for ITP.1 Effective first line therapies can circumvent the necessity for less-desirable second line therapies such as an invasive splenectomy or life-long treatment with thrombopoietin-receptor agonists (TPO-RAs) to increase platelet counts. ABBREVIATIONS:IVIG – intravenous immunoglobulin, ITP – primary immune thrombocytopenia, RhIG – Rh immune globulin, TPO-RAs – thrombopoietin-receptor agonists, MPV – mean platelet volume, RBC – red blood cell, HUS – hemolytic uremic syndrome, TTP – thrombotic thrombocytopenic purpura, DIC – disseminated intravascular coagulation, CBC – complete blood count, PT – prothrombin time, APTT – activated partial thromboplastin time, FDA – Food and Drug Administration" @default.
- W2912331585 created "2019-02-21" @default.
- W2912331585 creator A5027334267 @default.
- W2912331585 date "2016-04-01" @default.
- W2912331585 modified "2023-09-24" @default.
- W2912331585 title "Use of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia" @default.
- W2912331585 doi "https://doi.org/10.29074/ascls.29.2.92" @default.
- W2912331585 hasPublicationYear "2016" @default.
- W2912331585 type Work @default.
- W2912331585 sameAs 2912331585 @default.
- W2912331585 citedByCount "1" @default.
- W2912331585 countsByYear W29123315852022 @default.
- W2912331585 crossrefType "journal-article" @default.
- W2912331585 hasAuthorship W2912331585A5027334267 @default.
- W2912331585 hasBestOaLocation W29123315851 @default.
- W2912331585 hasConcept C109159458 @default.
- W2912331585 hasConcept C159654299 @default.
- W2912331585 hasConcept C203014093 @default.
- W2912331585 hasConcept C2776309230 @default.
- W2912331585 hasConcept C2777863708 @default.
- W2912331585 hasConcept C2779771385 @default.
- W2912331585 hasConcept C2780931953 @default.
- W2912331585 hasConcept C28328180 @default.
- W2912331585 hasConcept C54355233 @default.
- W2912331585 hasConcept C71924100 @default.
- W2912331585 hasConcept C86803240 @default.
- W2912331585 hasConcept C8891405 @default.
- W2912331585 hasConceptScore W2912331585C109159458 @default.
- W2912331585 hasConceptScore W2912331585C159654299 @default.
- W2912331585 hasConceptScore W2912331585C203014093 @default.
- W2912331585 hasConceptScore W2912331585C2776309230 @default.
- W2912331585 hasConceptScore W2912331585C2777863708 @default.
- W2912331585 hasConceptScore W2912331585C2779771385 @default.
- W2912331585 hasConceptScore W2912331585C2780931953 @default.
- W2912331585 hasConceptScore W2912331585C28328180 @default.
- W2912331585 hasConceptScore W2912331585C54355233 @default.
- W2912331585 hasConceptScore W2912331585C71924100 @default.
- W2912331585 hasConceptScore W2912331585C86803240 @default.
- W2912331585 hasConceptScore W2912331585C8891405 @default.
- W2912331585 hasLocation W29123315851 @default.
- W2912331585 hasOpenAccess W2912331585 @default.
- W2912331585 hasPrimaryLocation W29123315851 @default.
- W2912331585 hasRelatedWork W1970286080 @default.
- W2912331585 hasRelatedWork W1980651328 @default.
- W2912331585 hasRelatedWork W1989203399 @default.
- W2912331585 hasRelatedWork W2013116082 @default.
- W2912331585 hasRelatedWork W2052476260 @default.
- W2912331585 hasRelatedWork W2059857265 @default.
- W2912331585 hasRelatedWork W2078389048 @default.
- W2912331585 hasRelatedWork W2149724883 @default.
- W2912331585 hasRelatedWork W2361748627 @default.
- W2912331585 hasRelatedWork W2378385328 @default.
- W2912331585 hasRelatedWork W2435692022 @default.
- W2912331585 hasRelatedWork W2500818537 @default.
- W2912331585 hasRelatedWork W2618306508 @default.
- W2912331585 hasRelatedWork W2755042441 @default.
- W2912331585 hasRelatedWork W2978479910 @default.
- W2912331585 hasRelatedWork W3048501168 @default.
- W2912331585 hasRelatedWork W3147995253 @default.
- W2912331585 hasRelatedWork W3195801910 @default.
- W2912331585 hasRelatedWork W92943800 @default.
- W2912331585 hasRelatedWork W3091016487 @default.
- W2912331585 isParatext "false" @default.
- W2912331585 isRetracted "false" @default.
- W2912331585 magId "2912331585" @default.
- W2912331585 workType "article" @default.